UA129800C2 - Тверда форма івосиденібу - Google Patents

Тверда форма івосиденібу

Info

Publication number
UA129800C2
UA129800C2 UAA202100436A UAA202100436A UA129800C2 UA 129800 C2 UA129800 C2 UA 129800C2 UA A202100436 A UAA202100436 A UA A202100436A UA A202100436 A UAA202100436 A UA A202100436A UA 129800 C2 UA129800 C2 UA 129800C2
Authority
UA
Ukraine
Prior art keywords
ivosidenib
temperature
pharmaceutical composition
shchi
solid
Prior art date
Application number
UAA202100436A
Other languages
English (en)
Ukrainian (uk)
Inventor
Чун-Хой Ґу
Чун-Хой ГУ
Джейкоб Пол Сайзмор
Шицзе ЧЖАН
Original Assignee
Ле Лаборатуар Сервье
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ле Лаборатуар Сервье filed Critical Ле Лаборатуар Сервье
Publication of UA129800C2 publication Critical patent/UA129800C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UAA202100436A 2018-07-06 2019-07-02 Тверда форма івосиденібу UA129800C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862694596P 2018-07-06 2018-07-06
PCT/US2019/040257 WO2020010058A1 (en) 2018-07-06 2019-07-02 Ivosidenib forms and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
UA129800C2 true UA129800C2 (uk) 2025-08-06

Family

ID=69059942

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA202100436A UA129800C2 (uk) 2018-07-06 2019-07-02 Тверда форма івосиденібу

Country Status (18)

Country Link
US (1) US12264148B2 (https=)
EP (2) EP3817744A4 (https=)
JP (2) JP7621242B2 (https=)
KR (2) KR102919157B1 (https=)
CN (1) CN112367995A (https=)
AU (2) AU2019299352B2 (https=)
BR (1) BR112021000156A2 (https=)
CA (1) CA3103498A1 (https=)
EA (1) EA202190217A1 (https=)
IL (2) IL315423B1 (https=)
MA (1) MA53099A (https=)
MX (2) MX2021000068A (https=)
PH (1) PH12021550017A1 (https=)
SG (1) SG11202012763TA (https=)
TW (2) TWI902665B (https=)
UA (1) UA129800C2 (https=)
WO (1) WO2020010058A1 (https=)
ZA (1) ZA202008034B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4010331T (pt) 2019-08-08 2024-01-08 Servier Lab Um método de preparação do ivosidenib e de um seu intermediário
GB201912411D0 (en) * 2019-08-29 2019-10-16 Johnson Matthey Plc Crystalline forms of ivosidenib
AR133410A1 (es) 2023-08-01 2025-09-24 Servier Lab Cocristal de un inhibidor de idh1, proceso de preparación del mismo, composiciones farmacéuticas del mismo, y métodos de tratamiento que implican el mismo

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010223919B2 (en) 2009-03-13 2016-03-31 Les Laboratoires Servier Methods and compositions for cell-proliferation-related disorders
EP3561077B1 (en) 2009-10-21 2022-12-21 Les Laboratoires Servier Methods for cell-proliferation-related disorders
RU2013144975A (ru) * 2011-04-08 2015-05-20 Пфайзер Инк. Кристаллические и некристаллические формы тофацитиниба и фармацевтическая композиция, содержащая тофацитиниб, и усилитель проникновения
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
UY35006A (es) * 2012-09-06 2014-03-31 Bayer Healthcare Llc Composición farmacéutica recubierta que contiene regorafenib
BR122023021436A2 (pt) * 2014-03-14 2023-12-12 Les Laboratoires Servier Formas cristalinas e composição farmacêutica de compostos terapeuticamente ativos
KR20240010105A (ko) * 2014-03-14 2024-01-23 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
PT3362066T (pt) 2015-10-15 2021-11-16 Celgene Corp Terapia de combinação para tratar malignidades
ES2912909T3 (es) * 2016-02-26 2022-05-30 Celgene Corp Enasidenib para su uso en el tratamiento de la leucemia mieloide aguda recidivante o refractaria
WO2019104318A1 (en) 2017-11-27 2019-05-31 Teva Pharmaceuticals Usa, Inc. Solid state forms of ivosidenib

Also Published As

Publication number Publication date
TW202019419A (zh) 2020-06-01
TWI902665B (zh) 2025-11-01
EP4603147A2 (en) 2025-08-20
JP2021529805A (ja) 2021-11-04
JP2024150784A (ja) 2024-10-23
SG11202012763TA (en) 2021-02-25
MA53099A (fr) 2021-05-12
AU2019299352B2 (en) 2025-02-27
EP4603147A3 (en) 2025-10-01
IL279877A (en) 2021-03-01
TW202543623A (zh) 2025-11-16
BR112021000156A2 (pt) 2021-04-06
MX2021000068A (es) 2021-03-25
KR20210029775A (ko) 2021-03-16
US20210323944A1 (en) 2021-10-21
IL315423B1 (en) 2026-04-01
EA202190217A1 (ru) 2021-04-16
CN112367995A (zh) 2021-02-12
AU2025203835A1 (en) 2025-06-12
JP7621242B2 (ja) 2025-01-24
TWI911130B (zh) 2026-01-01
MX2023011687A (es) 2023-10-19
AU2019299352A1 (en) 2021-01-07
KR20250164882A (ko) 2025-11-25
ZA202008034B (en) 2021-10-27
CA3103498A1 (en) 2020-01-09
PH12021550017A1 (en) 2021-09-13
WO2020010058A1 (en) 2020-01-09
EP3817744A1 (en) 2021-05-12
US12264148B2 (en) 2025-04-01
IL315423A (en) 2024-11-01
EP3817744A4 (en) 2022-07-13
KR102919157B1 (ko) 2026-01-27

Similar Documents

Publication Publication Date Title
JP7801865B2 (ja) 治療活性化合物の医薬組成物
JP2021088605A (ja) 治療活性化合物の医薬組成物
JP2024150784A (ja) イボシデニブ形態および医薬組成物
EA048347B1 (ru) Формы ивосидениба и фармацевтические композиции
HK40129554A (en) Ivosidenib forms and pharmaceutical compositions
EA053032B1 (ru) Формы ивосидениба и фармацевтические композиции
HK40044696A (en) Pharmaceutical compositions of therapeutically active compounds and uses thereof
HK40043528A (en) Pharmaceutical compositions of therapeutically active compounds